



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

20th May 2026
IOLCP/CGC/2026

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051
Security Symbol: IOLCP

BSE Limited,
Pheroze Jeejeebhoy Tower,
Dalal Street, Mumbai- 400 001
Security Code: 524164

Subject: Press Release – Financial Results for the quarter and year ended 31st March 2026

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 20th May 2026 with respect to financial results for the quarter and year ended 31st March 2026.

Hope you will find the same in order.

Thanking You,

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Sr. Vice President & Company Secretary

IOL Chemicals and Pharmaceuticals Limited Reports Q4 & FY26 Results

Achieves Highest-Ever Quarterly Revenue with 15%+ EBITDA Margin

Ludhiana, 20th May 2026: IOL Chemicals & Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Financial Results for the quarter and full year ended 31st March 2026.

Q4 FY26 Financial Performance Snapshot (Y-o-Y)

(Standalone)


Revenue from Operations	EBITDA	PAT
₹ 619.5 Cr	₹ 94.3 Cr	₹ 53.2 Cr
▲ 17.4%	▲ 39.8%	▲ 68.2%

Key Standalone Financial Highlights

Particulars (₹ Cr)	Q4 FY26	Q4 FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenue from Operations	619.5	527.8	17.4%	2319.1	2079.2	11.5%
EBITDA	94.3	67.5	39.8%	290.4	224.6	29.3%
EBITDA Margin (%)	15.2%	12.7%	+251 bps	12.4%	10.7%	+172 bps
PAT	53.2	31.6	68.2%	137.7	101.0	36.4%
PAT Margin (%)	8.6%	5.9%	+262 bps	5.9%	4.8%	+108 bps

Segment Highlights

(In ₹ Cr)



Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,

“Q4FY26 marked a strong performance for IOL, with the Company delivering its highest-ever quarterly revenue, driven by healthy momentum across both Pharmaceuticals and Chemicals businesses. The quarter also witnessed significant improvement in profitability, with EBITDA and PAT recording strong growth, while margins expanded meaningfully on a YoY basis, supported by a better product mix and sustained focus on operational efficiencies.

The Pharmaceuticals business continued to demonstrate strong growth, led by increasing contribution from the non-Ibuprofen portfolio. Key products such as Paracetamol, Metformin, and other APIs witnessed healthy traction, reflecting the Company’s ongoing diversification strategy. The improving product mix, combined with IOL’s position as one of the lowest-cost producers in key molecules, supported stronger profitability and margin expansion in the Pharma segment. The company also continues to undertake capacity additions across select non-ibuprofen APIs as a part of its strategy to strengthen presence in value-added APIs.

The Chemicals business also delivered strong performance during the quarter, with segment EBIT nearly doubling YoY, supported by improved realizations, stable demand conditions, and operational efficiencies. Capacity enhancements in Ethyl Acetate, Acetic Anhydride along with addition of Triacetin Capacity will further strengthen the Company’s manufacturing capabilities, support backward integration and drive future growth.



During the year, the Company incurred capex of around Rs. 164 crore towards capacity expansion, product & infrastructure development, process automation, and operational improvements, funded through internal accruals. Looking ahead, IOL remains focused on driving disciplined expansion, deepening its presence in regulated as well as non-regulated markets, and enhancing operational efficiencies, supported by a diversified product portfolio and a strong execution track record.”



About IOL Chemicals and Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world’s largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP’s API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.

Contact Details

IOL Chemicals & Pharmaceuticals Ltd.	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L24116PB1986PLC007030	Ms. Prachi Ambre
Mr. Abhay Raj Singh Sr. VP & Company Secretary	prachi.ambre@in.mpms.mufg.com Mr. Irfan Raeen irfan.raeen@in.mpms.mufg.com
investor@iolcp.com	Meeting Request Link Website: https://in.mpms.mufg.com/

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.